Fig. 3: Effects of ENT1 inhibitors on cardiovascular function.
From: Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief
a, b Effects of intravenous (i.v.) injection of dilazep and JH-ENT-01 (30 mg/kg) on heart rates in ECG test, with representative ECG traces before the treatment and at 10 min, 30 min, and 60 min after the vehicle and drug treatment in a, quantification of heart rates as beats per min in b (n = 6 animals from both sexes). Two-way ANOVA followed by Bonferroni posthoc comparison. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. Figure 3b was created in BioRender. He, W. (2024) BioRender.com/f39n75. c, d Effects of intraperitoneal (i.p.) injection of dilazep and JH-ENT-01 (10 and 30 mg/kg) on heart rates in ECG test, with representative ECG traces before the treatment and at 10 min, 30 min, and 60 min after the vehicle and drug treatment in c, and quantification of heart rates as beats per min in d (n = 3 animals from both sexes). All data were expressed as mean ± s.e.m. Figure 3d was created in BioRender. He, W. (2024) BioRender.com/o52y585.
